Discovery platform for therapeutics development
Atreca’s proprietary discovery platform generates and develops therapeutics based on rapid characterization of human adaptive immune response at the single cell level. Foundation partners use the platform to isolate novel human monoclonal antibodies, gain immune response and vaccination insights, and generate new tools for global health vaccine discovery and development.
-
Domain
-
Investment typeDirect equity
-
StatusActive
-
Initial investmentSeries A
-
Partnered in2012
-
HeadquartersUSA
-
Program strategyDiscovery & Translational Sciences
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.